International Journal of Drug Delivery Technology
Volume 14, Issue 2

Revolutionizing Brain Tumor Therapy: Unleashing the Potential of Phytosomal Nanoparticles

Hitesha Gole, MS Manjusha Bhange*, Gunjan Rathod, Heena Mahurkar, Gaurav Kubde

Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education, Sawangi-Meghe, Wardha, Maharashtra, India. 

Received: 12th January, 2024; Revised: 21th March, 2024; Accepted: 16th April, 2024; Available Online: 25th June, 2024 

ABSTRACT

Unleashing the potential of phytosomal nanoparticles in brain tumor therapy. This article discusses the transforming potential of phytosomal nanoparticles in the fight against brain tumors, delving into this novel field. When the complex problems of traditional medicine are considered, the special qualities of phytosomal nanoparticles show great potential. Because of the nanoparticles’ ability to cross the blood-brain barrier, it is possible to transport drugs specifically to the brain, which solves a long-standing issue with current treatments. This accuracy reduces off-target effects, providing a crucial therapeutic benefit in a sensitive brain environment.

Phytosomal formulations are further distinguished by their lower toxicity and biocompatibility, which establishes them as a safer substitute for several traditional medicines. These natural compound-based nanoparticles fit in with the medical paradigm shift towards personalized and integrative care. The versatility of phytosomal formulations opens up new avenues for personalized medicine in the treatment of brain tumors by enabling customized approaches based on the molecular profiles of individual tumors.

Phytosomal nanoparticles provide a unique combination of natural pharmacopeia and state-of-the-art nanotechnology, which presents opportunities for novel therapeutic approaches beyond their clinical usefulness. The consequences could change the way brain tumors are treated as research and clinical trials are conducted. In order to overcome obstacles related to scalability, legal frameworks, and long-term safety assessments, cooperation between researchers, physicians, and legislators is essential. The full potential of phytosomal nanoparticles in the fight against brain tumors will be realized through ongoing research into how they might work in concert with current therapies and the creation of evidence-based guidelines. This article essentially presents a paradigm shift that will have a significant impact on cancer therapy in the future. It is the result of the convergence of innovative ideas inspired by nature with state-of-the-art nanotechnology.

Keywords: Phytosomal, Nanoparticles, Brain tumor therapy, Nanotechnology. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.79

How to cite this article: Gole H, Bhange MSM, Rathod G, Mahurkar H, Kubde G. Revolutionizing Brain Tumor Therapy: Unleashing the Potential of Phytosomal Nanoparticles. International Journal of Drug Delivery Technology. 2024;14(2):1130-1138.

REFERENCES

  1. Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella- Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta neuropathologica. 2016 Jun; 131:803-20.
  2. Isidro-Llobet A, Alvarez M, Albericio Amino acid-protecting groups. Chemical reviews. 2009 Jun 10;109(6):2455-504.
  3. Salehi B, Calina D, Docea AO, Koirala N, Aryal S, Lombardo D, Pasqua L, Taheri Y, Marina Salgado Castillo C, Martorell M, Martins N. Curcumin’s nanomedicine formulations for therapeutic application in neurological diseases. Journal of Clinical Medicine. 2020 Feb 5;9(2):430.
  4. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro-oncology. 2018 Oct 1;20(suppl_4):iv1-86.
  5. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley Structure and function of the blood–brain barrier. Neurobiology of disease. 2010 Jan 1;37(1):13-25.
  6. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell. 2010 Jan 19;17(1):98-110.
  7. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson Exciting new advances in neuro‐oncology: the avenue to a cure for malignant glioma. CA: a cancer journal for clinicians. 2010 May;60(3):166-93
  8. Meyers, A., & Brown, P. D. (2006). Role and relevance ofneurocognitive assessment in clinical trials of patients with CNS tumors. Journal of Clinical Oncology, 24(8), 1305-1309.
  9. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy- Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proceedings of the national academy of 2013 Nov 19;110(47):19059-64.
  10. Shakeri A, Sahebkar A, Javadi Melissa officinalis L.–A review of its traditional uses, phytochemistry and pharmacology. Journal of ethnopharmacology. 2016 Jul 21;188:204-28.
  11. Bonifacio BV, da Silva PB, Ramos MA, Negri KM, Bauab TM, Chorilli M. Nanotechnology-based drug delivery systems and herbal medicines: a review. International journal of nanomedicine. 2014 Dec 9:1-5.
  12. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human Planta medica. 1998 May;64(04):353-6.
  13. Gul A, Akhter Z, Perveen F, Kalsoom S, Ansari FL, Siddiq Molecular docking and quantitative structure activity relationship (QSAR) studies of some newly synthesized poly (azomethine) esters. International Journal of Polymer Science. 2019 Jan 17;2019.
  14. Lagoa R, Silva J, Rodrigues JR, Bishayee A. Advances in phytochemical delivery systems for improved anticancer Biotechnology advances. 2020 Jan 1;38:107382.
  15. Mitragotri S, Burke PA, Langer Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nature reviews Drug discovery. 2014 Sep;13(9):655-72.
  16. Upadhyay Drug delivery systems, CNS protection, and the blood brain barrier. BioMed research international. 2014 Oct;2014.
  17. Agrawal M, Tripathi DK, Saraf S, Saraf S, Antimisiaris SG, Mourtas S, Hammarlund-Udenaes M, Alexander A. Recent advancements in liposomes targeting strategies to cross blood- brain barrier (BBB) for the treatment of Alzheimer’s disease. Journal of controlled release. 2017 Aug 28;260:61-77.
  18. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell. 2010 Jan 19;17(1):98-110.
  19. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Advanced drug delivery reviews. 2011 Mar 18;63(3):131-5.
  20. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, Chan Analysis of nanoparticle delivery to tumours. Nature reviews materials. 2016 Apr 26;1(5):1-2.
  21. Sollini M, Bartoli F, Marciano A, Zanca R, Slart RH, Erba PA. Artificial intelligence and hybrid imaging: the best match for personalized medicine in oncology. European journal of hybrid imaging. 2020 Dec;4(1):1-22.
  22. Gupta A, Eral HB, Hatton TA, Doyle Nanoemulsions: for mation, proper ties and applications. Sof t mat ter. 2016;12(11):2826-41.